Vertex Pharmaceuticals (VRTX) Payables: 2009-2025
Historic Payables for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $420.3 million.
- Vertex Pharmaceuticals' Payables rose 6.19% to $420.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 19.49%. This contributed to the annual value of $413.0 million for FY2024, which is 13.18% up from last year.
- Per Vertex Pharmaceuticals' latest filing, its Payables stood at $420.3 million for Q3 2025, which was down 4.97% from $442.3 million recorded in Q2 2025.
- In the past 5 years, Vertex Pharmaceuticals' Payables ranged from a high of $445.0 million in Q1 2025 and a low of $126.9 million during Q3 2022.
- In the last 3 years, Vertex Pharmaceuticals' Payables had a median value of $375.9 million in 2023 and averaged $383.9 million.
- In the last 5 years, Vertex Pharmaceuticals' Payables soared by 196.22% in 2023 and then declined by 9.67% in 2024.
- Vertex Pharmaceuticals' Payables (Quarterly) stood at $195.0 million in 2021, then spiked by 55.85% to $303.9 million in 2022, then increased by 20.07% to $364.9 million in 2023, then increased by 13.18% to $413.0 million in 2024, then rose by 6.19% to $420.3 million in 2025.
- Its last three reported values are $420.3 million in Q3 2025, $442.3 million for Q2 2025, and $445.0 million during Q1 2025.